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Background: Many arteriovenous fistula (AVF) fail prior to use due to lack of maturation or thrombosis. Determining
vascular function prior to surgery may be helpful to predict subsequent AVF success. This is a feasibility study to
describe the vascular function in a cohort of chronic kidney disease (CKD) patients who are awaiting AVF creation.
Methods: A prospective cohort of 28 CKD patients expected to progress to HD underwent arterial stiffness (pulse
wave velocity, PWV) and endothelial function testing (flow mediated dilation FMD, and peripheral arterial tonometry,
PAT) one week prior to AVF creation. AVF success was defined as maintaining patency and achieving maturation.
Post operative fistula assessment at 8 weeks evaluated maturation (clinical assessment of adequate fistula
flowand ultrasound diameter ≥ 0.5 cm).
Results: The median age 72 years (62 - 78), 75% males, eGFR 15 ml/min/1.73 m2 (12 – 18). 20 (71%) patients had
successful AVF surgery with a mature AVF at 8 weeks. Patients with AVF success had higher mean PAT values
1.87 ± 0.52 than those with failed AVF 1.41 ± 0.24 p = 0.03.
Conclusions: Microvascular endothelial function as measured using PAT may be useful as a predictor of AVF
maturation and function. This simple non invasive marker of vascular function may be a useful tool to predict
AVF outcomes.
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Contexte: On attribue l’échec précoce de plusieurs fistules artérioveineuses (FAV) à un manque de maturation ou à
une thrombose précoce. Une évaluation de la fonction vasculaire en phase préopératoire pourrait aider à prédire
l’issue d’une FAV prochaine. Ceci est une étude de faisabilité de l’évaluation de la fonction vasculaire d’une cohorte
de patients atteints d’insuffisance rénale chronique (IRC) en attente de confection de FAV.
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Méthode: L’étude de cohorte prospective comprenait 28 patients atteints d’une IRC évoluant vers des traitements
d’hémodialyse. Une semaine avant la confection de la FAV, les participants ont subi des évaluations de la rigidité
artérielle (analyse de l’onde de pouls) et de la fonction endothéliale (mesure de la vasodilatation médiée par le flux
[flow-mediated dilatation ou FMD] et tonométrie artérielle périphérique ou EndoPAT) une semaine avant la
confection de la FAV. Nous définissons le succès de la FAV comme le maintien de la perméabilité et l’atteinte de sa
maturité. L’examen postopératoire de la fistule, 8 semaines après l’intervention, évaluait sa maturation (examen
clinique du débit adéquat de la fistule, et évaluation du diamètre par ultrasons, soit ≥ 0,5 cm.).
Résultats: L’âge moyen des participants était de 72 ans (62 – 78); 75% des participants étaient de sexe masculin. Le
DFG estimé était de 15 ml/min/1,73 m2 (12 – 18). Le succès de la confection et la maturation de la FAV à 8
semaines ont été évalués auprès de 20 patients (71%). Les valeurs moyennes de l’EndoPAT étaient plus élevées
chez les FAV complétées avec succès (1,87 ± 0,52), que chez les FAV en échec précoce (1,41 ± 0,24 p = 0,03). Après
redressement de l’échantillon pour l’âge, le sexe et le DFG, l’EndoPAT était lié au succès de la FAV (pour chaque
augmentation à l’EndoPAT, le taux de succès de la FAV était multiplié par 1,75; p = 0,02).
Conclusions: La fonction microvasculaire endothéliale évaluée par EndoPAT pourrait être utilisée pour prédire la
maturation et le fonctionnement d’une FAV. Cet indicateur simple et non invasif de la fonction vasculaire pourrait
être également un outil pratique pour prédire le résultat de la confection d’une FAV.Background
Chronic kidney disease patients (CKD) have a large bur-
den of vascular disease which contributes to their mor-
bidity and leads to increased mortality. A thorough
characterization of the vascular function of CKD pa-
tients may allow us to better predict the vascular out-
comes in these patients. Once CKD patients progress to
end stage renal disease, a functioning, reliable vascular
access (VA) is crucial for the delivery of adequate
hemodialysis (HD). A vascular access allows blood to be
delivered to the dialysis machine and can be in the form
of a fistula (AVF), graft or a central venous catheter.
Studies consistently demonstrate that AVF are the pre-
ferred type of VA as they provide the highest blood flow,
suffer from the fewest complications [1] (such as sten-
osis or infection), and have the longest survival [2], and
lowest associated mortality as compared to either cathe-
ters or grafts. Unfortunately anywhere from 30 to 61% of
fistula will fail prior to their use for hemodialysis either
due to lack of vessel maturation or spontaneous throm-
bosis [3]. A better understanding of the patient’s vascula-
ture may help predict which patients are at highest risk
of fistula failure.
A number of measures are available to assess vascular
function and predict future cardiovascular risk such as
pulse wave velocity (PWV) and flow mediated dilation
(FMD) of the brachial artery. PWV characterizes arterial
stiffness and is a strong independent predictor of cardio-
vascular mortality in both end-stage kidney patients [4]
and the general population [5]. FMD provides an assess-
ment of macrovascular endothelial cell function. Healthy
endothelium releases a potent vasodilator (nitric oxide,
NO) in response to ischemic stress such as cuff occlu-
sion of the brachial artery. FMD is a measure of thechange in the brachial artery diameter in response to
cuff occlusion and subsequent NO release. Whereas
FMD reflects the ability of a large artery to vasodilate,
the subsequent change in blood flow that ensues repre-
sents the health of the peripheral resistance vessels or
microvascular function. Microvascular endothelial func-
tion can be characterized by the velocity time integral
(VTI) of the hyperemic velocity [6] or the pulse wave
amplitude during reactive hyperemia. Peripheral arterial
tonometry (PAT) [7,8] provides a measure of the pulse
wave amplitude with reactive hyperemia, and when nor-
malized to the baseline, it gives an index or a ratio with
higher values representing better vascular health. Indi-
viduals with coronary artery disease (CAD) have been
shown to have an impaired FMD response [9], a reduced
VTI [6] and low PAT index [10]. These measures have
also been shown to predict the development of cardio-
vascular disease in the general population [11] although
literature amongst CKD patients is limited [12].
The primary objective of this study was twofold: to de-
scribe the arterial stiffness (PWV) and endothelial func-
tion markers (FMD, VTI and PAT) in a cohort of CKD
patients referred for access creation and to determine
the feasibility of using these vascular health markers as
predictors of successful fistula maturation at 8 weeks
post fistula creation. Secondary objectives were to deter-
mine if patient characteristics (age, diabetes status,
CAD) were associated with successful AVF maturation
and use. We hypothesized that measures of vascular
health are associated with VA outcomes in the CKD
population and that patients in whom an AVF was suc-
cessfully created and matured would have better vascu-
lar health parameters than those in whom an AVF was
unsuccessful.
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This was a prospective cohort study of CKD patients,
18 years or older, with an estimated glomerular filtration
rate (eGFR) < 20 ml/min/1.73 m [2], who were expected
to progress to hemodialysis and who had been referred
for surgical assessment for possible AVF creation. Within
this cohort there was a group of patients who were re-
ferred to the vascular access surgeons for planned fistula
creation (and not just for a surgical assessment only).
These patients received a date for planned AVF creation
and are the focus of the current study. All patients, includ-
ing those who were sent for a surgical assessment only,
underwent vascular health testing; however amongst the
patients with a planned AVF surgery this testing was done
1 week prior to the AVF creation date. Patients were ex-
cluded if they did not fast for 10 hours or had taken anti-
hypertensive medication the morning of the testing. This
study was approved by the University of Calgary Research
Ethics Board and all subjects gave written informed con-
sent. Demographic and clinical data were abstracted from
the Southern Alberta Renal Program Database including
patient characteristics such as age, gender, smoking status
and comorbidities of diabetes mellitus (DM), CAD, per-
ipheral vascular disease (PVD), congestive heart failure
(CHF) and cerebrovascular disease (CVA).
Vascular health testing
FMD, VTI, PWV, PAT and blood pressure were mea-
sured in the non-dominant arm one week prior to
scheduled AVF creation. Patients fasted for at least
10 hours (including abstinence from caffeine, vasoactive
medications, nicotine and alcohol) prior to testing. All
studies were performed following a standardized procedure
by a single operator at 23 C in the Endothelial Function
Laboratory, Department of Cardiac Sciences, University of
Calgary, Calgary, Canada. Patients rested for 5 minutes in a
supine quiet position prior to blood pressure measure-
ments (Welch Allyn Canada Ltd., Mississauga, ON) mea-
sured in duplicate. Baseline PWV measurements were
taken using applanation tonometry (Sphygmacor Version
8,0, Atcor Medical), a non invasive pressure tonometer
probe that was sequentially placed on the carotid and ra-
dial artery of the supine resting subject’s non-dominant
arms. All PWV measurements were taken by the same per-
son. The speed at which the pulse wave travels between
the carotid and radial artery was determined using gated
electrocardiographic data and translated into a pulse wave
velocity. Augmentation index was calculated as the differ-
ence between the first and second aortic systolic peaks nor-
malized to the pulse pressure [13].
FMD was determined using a high resolution ultrasound
(SONOS 5500; Phillips Medical Systems, Andover, MA)
equipped with 10 MHz linear array vascular transducers
to measure the brachial artery diameter at baseline andwith hyperemia. After baseline measurements of the bra-
chial artery diameter and velocity were obtained, a blood
pressure cuff was inflated to 200 mmHg or 50 mmHg
above the systolic pressure on the distal portion of the
non-dominant arm for 5 minutes to create distal limb is-
chemia. After release of the cuff, reactive hyperemia oc-
curs and the flow in brachial artery increases. The peak
brachial artery diameter for calculation of FMD was deter-
mined between 45 seconds and 2 minutes after cuff re-
lease. VTI was determined as the first full envelope after
cuff release. Further details of FMD analysis are presented
elsewhere [14]; FMD was calculated as: (hyperemic bra-
chial artery diameter – baseline brachial artery diameter)/
baseline diameter x 100%. All measurements of the FMD
were obtained by one trained individual.
The PAT device (Itamar Medical, Caesaria, Israel) uses a
pressure sensor to measure the arterial component of the
fingertip volume changes that accompany the pulse wave.
This fingertip plethysmograph is placed on the index fin-
ger of each hand for PAT assessment of the control (dom-
inant arm) and ischemic limb (non dominant arm). The
PAT signal is recorded continuously at baseline, through-
out cuff occlusion and immediately after occlusion in order
to give an index of the peak hyperemic fingertip volume to
the baseline ratio normalized to the control arm. Measure-
ments of PAT, VTI and FMD were taken simultaneously.
Details of the PAT index are described elsewhere [7].
Biomarkers of vascular health (high sensitivity C reactive
protein (hs-CRP), and parathyroid hormone (PTH) were
obtained along with other laboratory values (hemoglobin,
albumin, and creatinine)) at baseline coinciding with the
time of vascular parameter measurement.
Outcomes
Amongst CKD patients progressing to AVF creation the
association between the vascular health parameters and
AVF success at 8 weeks was explored. AVF success was
defined as maintaining patency (thrill present) and achiev-
ing functional maturation. Post operative fistula assess-
ment was done 8 weeks after creation to evaluate the
maturation status of the fistula. Maturation was deter-
mined with ultrasound criteria of AVF diameter > 5 mm
and adequate flow criteria assessed by the presence of a
strong thrill at the anastamosis [15]. Maturation assess-
ments done at 6 to 8 weeks post creation have been shown
to predict the ability of the AVF to support dialysis with a
mature AVF providing a functional AVF at dialysis start
[15]. Dialysis suitability was defined as ability to support
dialysis without the need for an alternate access in the first
month of dialysis initiation.
Statistical analysis
The primary outcome of this study was AVF success (pa-
tent and mature) at 8 weeks post creation. Baseline patient
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were compared between the patients with successful AVF
and those with unsuccessful AVF. Categorical variables
were represented by frequency (percentage) and compari-
sons were made via the Chi-square or Fisher’s Exact test.
Underlying distributions of continuous variables were
tested for normality using the Shapiro-Wilk test. Normally
distributed variables were represented as mean (standard
deviation) and comparisons were made using the Student’s
t-test. Variables not normally distributed were represented
by median (interquartile range) and comparisons were
conducted using the Wilcoxon rank test. All analyses were
performed using SAS 9.2 (Cary, NC, USA).Results
We recruited 52 stage IV/V CKD patients to the study
(37 men, 15 women) from June 1, 2006 until June 1,
2010, of whom 28 underwent AVF surgery and are the
focus of this study (Figure 1). Patients were followed for
one year after study entry to allow for dialysis initiation
and functional assessment of the AVF (until June 1,
2011). Table 1 shows the baseline characteristics for the
entire cohort as well as the 28 who underwent AVF sur-
gery. The AVF patient population was older (median age
72), mostly males with a median eGFR of 15 ml/min/
1.73 m [2] who had controlled blood pressure (median
BP 135/78) with significant proteinuria (median protein
to creatinine ratio of 0.36 corresponding to over 3 grams
of protein/day) (Table 1). The majority of the study sub-
jects had co-morbidities of: hypertension (100%), diabetes
(56%), dyslipidemia (62%) and CAD (50%), reflective of a
typical CKD population (Table 1). The mean time fromFigure 1 Patient Flow Diagram. Description of patient flow from start ofAVF creation until dialysis initiation for this cohort was
12.9 ± 13 months.
Fistula success
Of the 28 patients who underwent AVF surgery, 20 were
successful and led to a mature AVF at 8 weeks. Amongst
the 20 mature AVF, 18 were in use at HD start. The time
from AVF creation until HD start was 11 ± 9.5 months
for these patients. One patient had not yet started HD
and another died before HD initiation. Of the unsuccess-
ful AVF (8/28, 30%): 2 failed attempted AVF creation, 2
thrombosed post surgery, 4 failed to mature, and 1 was
ligated at 6 weeks due to complications of steal. We did
not find any significant differences in patient characteris-
tics between those with a successful or unsuccessful
AVF. The eGFR at the time of AVF creation (15 ml/min)
and the degree of albuminuria (approximately 2.8 g
albumin/day) was similar between the two groups of pa-
tients. Although not statistically significant the patients
with successful AVF were mostly male (80% vs 63% in
unsuccessful AVF, P = 0.33) and younger (71 vs 75 years,
P = 0.54). The proportion of patients with diabetes and
hypertension was similar amongst patients with suc-
cessful and unsuccessful AVF.
The vascular function parameters are depicted in
Table 2. The median FMD of 5.7 ± 4.3% in our study pa-
tients is lower than what has been reported in the gen-
eral population [6]. The PAT was also low (1.73 ± 0.5)
and similar to what has been reported for patients with
CAD [16].
When comparing the patients with successful AVF to
those with unsuccessful AVF we found very similar values
in both groups for the FMD, PWV and VTI (Table 2). Thestudy to completion.
Table 1 Patient characteristics
Variable AVF creation (%), n = 28 No AVF creation (%), n = 24 Entire cohort (n = 52)
Age 72 (62-78) 71 (51-77) 71.5 (59.5 - 77.5)
Gender: Male 21 (75%) 16 (67%) 37 (71%)
Etiology of CKD
Diabetes mellitus 8 (29%) 7 (29%) 15 (29%)
Hypertension 9 (32%) 5 (21%) 14 (27%)
Glomerulonephritis 1 (4%) 3 (13%) 4 (8%)
Obstruction 1 (4%) 2 (8%) 3 (6%)
Other 9 (32%) 7 (29%) 16 (31%)
Diabetes mellitus 14 (56%) 14 (58%) 28 (57%)
Hypertension 27 (100%) 22 (92%) 49 (96%)
Coronary artery disease, CAD 5 (50%) 5 (45%) 10 (48%)
Family history of CAD 1 (9%) 2 (18%) 3 (14%)
Smoker 4 (15%) 3 (13%) 7 (14%)
Peripheral vascular disease 3 (27%) 3 (27%) 6 (27%)
Dyslipidemia 8 (62%) 7 (58%) 15 (60%)
eGFR, ml/min/1.7 m2 15 (12-18) 24 (19-31) 17.5 (13 - 25)
Laboratory variables
Hemoglobin, g/L 121 ± 14 121 ± 16) 121 (15)
Creatinine, umol/L 343 ± 88 231 ± 57) 291.54 ± 93.54
Urine microalbumin: creatinine ratio 285 (80-377) 15 (9-111) 95.7 (11.3 - 295)
Urine Protein: Cr ratio 0.36 (0.10-0.49) 0.03 (0.02-0.14) 0.11 (0.03 - 0.38)
Systolic blood/diastolic pressure left arm 135 (127-153)/78(70-88) 125 (115-148)/75 (68-83) 131.5 (119 - 149)/76 (69 – 85)
Mean arterial pressure 94 (89-106) 93 (84-101) 94 (87.67 - 104)
Beta blocker 8 (29) 3 (12) 11 (21)
Statin 9 (32) 5 (21) 14 (27)
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successful AVF (1.87 ± 0.52) than those with failed AVF
(1.41 ± 0.24 p = 0.03). The analysis was repeated with the
ligated AVF included in the successful category (instead of
unsuccessful as reported above) and all results remained
similar (data not shown).Table 2 Vascular Function Tests amongst the AVF cohort
Variable Ove
PWV, mean ± SD, m/s left arm 8.4 ±
Peripheral arterial tonometry, mean ± SD 1.73
Brachial artery diameter baseline; mean ± SD mm 4.7 ±
Velocity time integral baseline; mean ± SD, ml 15.3
Brachial artery– flow baseline; mean ± SD, ml/min 191
Brachial artery diameter with reactive hyperemia; mean ± SD mm 5.1 ±
Velocity time integral with reactive hyperemia; mean ± SD, ml 63 (3
Brachial artery flow, with reactive hyperemia; mean ± SD, ml/min 838
Flow Mediated Dilation; mean ± SD, % 5.7 (Discussion
In this exploratory study we found that it is feasible to
obtain vascular health parameters in a cohort of CKD
patients prior to AVF creation. Our preliminary findings
suggest that microvascular endothelial function as mea-
sured using PAT may be associated with subsequentrall AVF outcome P-value
Unsuccessful n = 8 Successful n = 20
1.7 8.2 ± 2.2 8.5 ± 1.5 0.70
(0.50) 1.41 (0.24) 1.87 (0.52) 0.03
0.8 4.5 ± 0.8 4.8 ± 0.8 0.41
(4.9) 16.4 (6.7) 14.9 (4.1) 0.47
(92) 176 (92) 197 (94) 0.60
0.8 4.9 ± 0.8 5.1 ± 0.9 0.58
3) 80 (50) 57 (23) 0.10
(458) 884 (408) 818 (486) 0.74
4.3) 7.7 (5.9) 4.9 (3.3) 0.12
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small sample size we are unable to find any associations
between the vascular health parameters of PWV, FMD
or VTI and subsequent AVF success.
PAT is an accepted measure of microvascular endothe-
lial function in the general population and those with
cardiovascular disease and is known to be markedly de-
creased in individuals with CAD [17]. To our knowledge
PAT has not been previously tested in the CKD popula-
tion nor has it been used as a predictor of AVF matur-
ation or success.
PAT is predominantly a measure of the peripheral
small vessel function and is in part NO dependent. How-
ever, the stimuli that prompts the microvasculature to
dilate to shear stress likely depends on other mediators
such as prostaglandins, adenosine, potassium- ATP
channels and endothelial derived hyperpolarizing factor
[18]). The other marker of microvascular endothelial
function, VTI was recently found to correlate with PAT,
although this association is weak [19]. Given that VTI is
measured using the brachial artery it may be that PAT
and VTI measure two different microvascular beds and
that the peripheral small vessel function is a better de-
terminant of AVF success.
Hyperemic velocity or VTI has been suggested to be a
better predictor of cardiac outcomes than FMD [6,20]
because it is in fact the stimuli for FMD. The hyperemic
velocity reflects both the endothelial function (the ability
to release NO) and the endothelial structure (the ability
to respond to hyperemia). In this study our CKD pa-
tients had a blunted reactive hyperemia response as
compared to normal subjects [6] but this vascular
marker was not predictive of subsequent AVF success.
We are not aware of other studies exploring the VTI in
CKD patients although there are reports of abnormal
endothelial health [21].
Our study patients had impaired FMD with a median
value of 5.0% (3-9) but we did not find any difference
between the patients with successful and unsuccessful
AVF. The finding of impaired endothelial function in
this CKD cohort is similar to others have shown using
both venous occlusion plethysmography techniques [12],
and FMD [22]. To date, there are two other studies
[23,24] that explore the relationship between FMD and
AVF creation. Owens et al [23] determined FMD
amongst 25 CKD patients prior to AVF creation and
found very similar values to ours (5.8 ± 1.0%). They ex-
plored the correlation between baseline FMD and subse-
quent change in the diameter of the artery and vein at
3 months after AVF creation and found a positive correl-
ation. Unlike in our study, they did not perform a mat-
uration or functional assessment of the AVF and thus
whether these changes in vascular diameter correlated to
maturation or function is unknown. In our study weperformed both a maturation assessment as well as a
functional assessment at the time of dialysis start and all
of our AVF that we had deemed mature were indeed
functional at the time of dialysis initiation. We did not
record the final diameter of the AVF but it is unlikely
that we would have found a significant correlation given
that our definition of mature AVF included a diame-
ters ≥ 5 mm in accordance with the standard definition
of mature AVF.
Genek et al [24] performed radial and brachial artery
measurements, peak systolic blood flow rate and FMD
prior to AVF creation. AVF assesments were made at
48 h post op and at day 30. Similar to our study, they
did find any associations with FMD and subsequent AVF
success but their period of follow up was relatively short.
PWV can decrease with the creation [25,26] of an AVF
but it has not been previously explored as a predictor of
AVF success. We did not find an association between
underlying arterial stiffness in the periphery and subse-
quent AVF outcome. This probably reflects that regard-
less of the underlying stiffness of the vasculature, the
more important aspect is the ability of the artery and
vein to dilate and maintain the increase in blood flow re-
quired by successful AVF creation.
Maturation of an AVF is a complex process and not
well understood. The factors that lead to a mature and
functional AVF include: technical factors such as surgical
expertise, location and angle of anastomosis [27], vascu-
lar health factors (diameter of vessels [28], endothelial
function [23]) and patient factors such as elevated blood
viscosity [29] leading to thrombosis. It is likely that one
of the most important determinants of AVF maturation
is the ability of the inflow artery and the outflow vein to
respond to the increased blood flow that occurs upon
anastomosis of the artery and vein. A healthy response
to the anastomosis is an increase in blood flow and cor-
responding increase in shear stress [15] which stimulates
the endothelial cells to release NO and other vasodila-
tory substances [30]. Many studies [26,31,32] have
shown that there is first an immediate increase in blood
flow upon anastomosis of artery to vein and subse-
quently the vein diameter increases. It is possible that
the microvascular function, specifically the ability to di-
late in response to the altered shear stress is a predictor
of AVF success.
Studies are conflicting regarding the factors that are
associated with AVF success. Most studies show that age
[33], CAD and PVD are associated with a lower likeli-
hood of a successful AVF [34,35]. However, diabetes
[36,37] and female gender [38] are also associated with
AVF failure in some but not all studies. Age, gender, DM
and CAD were not predictive of AVF outcome in our
cohort but this is likely due to our small sample size. In
addition, within each of these patient factors there may
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health and perhaps a better predictor is something that
can more accurately reflect the endothelial function and
structure such as PAT.
In this study we examined the response of the endo-
thelium to the ischemic stress of brachial artery occlu-
sion and measured the subsequent changes in diameter
of artery and the blood flow velocity. Eight weeks after
AVF creation successful AVF dilated to 5 mm or greater
and they had a higher fingertip volume in response to
reactive hyperemia. Since AVF maturation is dependent
on endothelial function and the ability to respond to
shear stress it seems logical that markers of endothelial
function such as VTI and FMD may be predictive of
maturation abilities. In our study however, we only
showed an association with PAT and not VTI or FMD.
The main limitation of this study is the small sample
size and the observational nature of the study. As pilot
data these findings are intriguing and should be pursued
in a larger study to determine if measures of micro-
vascular endothelial function (PAT) predict successful
AVF maturation. In addition, our patient population is
predominantly male which limits the generalizability; it
may be that there is some selection bias on the part of
the nephrologist to refer females for AVF assessment.
Furthermore, this CKD population was selected from in-
dividuals who are attending multidisciplinary Kidney
Function Clinics which may limit the generalizability of
the findings as these patients may represent a healthier
patient population than those not followed at Kidney
Function Clinics.Conclusions
The ability to have a reliable predictor of AVF success
would be useful in the management of the pre-dialysis
CKD patient. In individuals with poor prognostic factors
for AVF success, conversations regarding the option of
peritoneal dialysis could be reinforced or alternate
choices of vascular access could be reviewed. Currently
there are no established tools for predictors of AVF out-
come, however, microvascular endothelial function as
determined using PAT may be a useful tool which re-
quires further exploration with a larger sample size.
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